ABP 938 vs Aflibercept for Age-Related Macular Degeneration

This trial tests two treatments, ABP 938 and aflibercept, to determine their effectiveness for individuals with neovascular age-related macular degeneration (nAMD), a condition that can lead to vision loss. Researchers aim to measure how these treatments affect vision clarity over time. Participants will receive eye injections of either treatment and attend regular check-ups to adjust dosing based on their condition. This trial may suit individuals aged 50 and older who have been newly diagnosed with nAMD and experience fluid buildup in the eye that affects vision. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial does not specify if you need to stop taking your current medications, but it does exclude those who have had prior or current treatment with certain eye medications or surgeries for the study eye. It's best to discuss your specific medications with the trial team.

Previous studies have shown that ABP 938 is as safe as aflibercept for treating age-related macular degeneration (AMD). Research indicates no major safety differences between ABP 938 and aflibercept. Both treatments have similar side effects and are generally well-tolerated by patients. Participants in these studies did not experience unusual or severe side effects. This information provides confidence in the overall safety of ABP 938 for those considering joining a clinical trial.¹²³⁴⁵

Researchers are excited about ABP 938 for age-related macular degeneration (AMD) because it offers a promising alternative to standard treatments like Aflibercept. Unlike typical therapies that require frequent injections, ABP 938 is designed to potentially extend the interval between doses, offering patients more convenience and possibly better compliance. Additionally, ABP 938 targets similar pathways as existing options but may provide improved efficacy or safety, making it a hopeful option for those with AMD.

This trial will compare ABP 938 with Aflibercept for treating neovascular age-related macular degeneration (nAMD), which affects vision. Studies have shown that ABP 938 is as effective as Aflibercept in treating nAMD. Research indicates no major differences in how well these treatments improve eyesight. In one study, patients using ABP 938 improved by an average of 6.4 letters on a vision test by week 8. This finding suggests that ABP 938 is as effective as Aflibercept in helping people with nAMD maintain or improve their vision. Both treatments have been found safe and effective, with consistent results across multiple studies.¹²³⁴⁶